Shuk-Mei Ho
Concepts (536)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Phenols | 27 | 2025 | 82 | 7.370 |
Why?
| Benzhydryl Compounds | 25 | 2021 | 64 | 6.630 |
Why?
| Prostatic Neoplasms | 32 | 2022 | 384 | 5.320 |
Why?
| Prostate | 22 | 2020 | 114 | 3.990 |
Why?
| Epigenesis, Genetic | 16 | 2025 | 372 | 3.620 |
Why?
| Endocrine Disruptors | 16 | 2025 | 32 | 3.590 |
Why?
| Estradiol | 19 | 2021 | 221 | 3.370 |
Why?
| DNA Methylation | 19 | 2025 | 550 | 3.310 |
Why?
| Estrogen Receptor beta | 17 | 2019 | 55 | 3.090 |
Why?
| Prenatal Exposure Delayed Effects | 8 | 2021 | 182 | 2.380 |
Why?
| Gene Expression Regulation, Neoplastic | 19 | 2024 | 833 | 2.200 |
Why?
| Environmental Pollutants | 7 | 2024 | 102 | 1.710 |
Why?
| Maternal Exposure | 5 | 2025 | 96 | 1.660 |
Why?
| Testosterone | 8 | 2016 | 145 | 1.650 |
Why?
| Air Pollutants, Occupational | 4 | 2020 | 17 | 1.550 |
Why?
| Occupational Exposure | 4 | 2021 | 113 | 1.490 |
Why?
| Estrogens | 12 | 2020 | 226 | 1.480 |
Why?
| Spermatogenesis | 2 | 2021 | 9 | 1.300 |
Why?
| Environmental Exposure | 8 | 2024 | 199 | 1.280 |
Why?
| Diet, High-Fat | 4 | 2021 | 214 | 1.180 |
Why?
| Animals | 51 | 2024 | 13124 | 1.170 |
Why?
| Rats | 24 | 2021 | 3292 | 1.160 |
Why?
| Male | 64 | 2022 | 25913 | 1.130 |
Why?
| Breast Neoplasms | 10 | 2016 | 1200 | 1.100 |
Why?
| Receptors, Estrogen | 6 | 2019 | 132 | 1.010 |
Why?
| Gene Expression Profiling | 10 | 2015 | 1025 | 1.010 |
Why?
| Centrosome | 2 | 2016 | 11 | 1.000 |
Why?
| Mammary Neoplasms, Experimental | 2 | 2017 | 121 | 0.990 |
Why?
| Cell Line, Tumor | 23 | 2024 | 1398 | 0.950 |
Why?
| Veterans | 2 | 2021 | 574 | 0.930 |
Why?
| Butter | 2 | 2021 | 4 | 0.900 |
Why?
| Adenocarcinoma | 5 | 2015 | 396 | 0.900 |
Why?
| Pregnancy | 17 | 2025 | 2451 | 0.890 |
Why?
| Humans | 73 | 2025 | 50516 | 0.880 |
Why?
| Metallothionein | 2 | 2015 | 8 | 0.840 |
Why?
| Cell Movement | 4 | 2014 | 247 | 0.830 |
Why?
| Female | 44 | 2025 | 27086 | 0.810 |
Why?
| Rats, Sprague-Dawley | 14 | 2021 | 1585 | 0.800 |
Why?
| Promoter Regions, Genetic | 9 | 2019 | 465 | 0.800 |
Why?
| Response Elements | 2 | 2013 | 29 | 0.800 |
Why?
| CpG Islands | 7 | 2025 | 108 | 0.770 |
Why?
| Infertility, Male | 1 | 2021 | 12 | 0.760 |
Why?
| Estrogens, Non-Steroidal | 8 | 2015 | 16 | 0.760 |
Why?
| Signal Transduction | 14 | 2020 | 1624 | 0.750 |
Why?
| Cell Proliferation | 10 | 2017 | 985 | 0.740 |
Why?
| Dietary Fats | 1 | 2021 | 125 | 0.720 |
Why?
| Toxicity Tests | 1 | 2020 | 54 | 0.700 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 43 | 0.690 |
Why?
| Racemases and Epimerases | 2 | 2011 | 17 | 0.680 |
Why?
| MicroRNAs | 4 | 2016 | 344 | 0.650 |
Why?
| Aging | 4 | 2017 | 694 | 0.640 |
Why?
| Gene Regulatory Networks | 3 | 2017 | 106 | 0.640 |
Why?
| Asthma | 2 | 2013 | 284 | 0.640 |
Why?
| Prostatic Intraepithelial Neoplasia | 4 | 2015 | 8 | 0.630 |
Why?
| Epigenomics | 2 | 2016 | 68 | 0.610 |
Why?
| Military Personnel | 1 | 2020 | 163 | 0.610 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2016 | 572 | 0.610 |
Why?
| Stress, Psychological | 1 | 2020 | 266 | 0.610 |
Why?
| Benzo(a)pyrene | 3 | 2017 | 12 | 0.600 |
Why?
| Chromosomes, Human, X | 1 | 2018 | 18 | 0.600 |
Why?
| Anxiety | 1 | 2020 | 285 | 0.600 |
Why?
| Depressive Disorder | 1 | 2020 | 335 | 0.590 |
Why?
| Reproduction | 2 | 2016 | 56 | 0.590 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2016 | 49 | 0.580 |
Why?
| Disease Susceptibility | 3 | 2012 | 88 | 0.580 |
Why?
| Embryonic Development | 2 | 2015 | 16 | 0.570 |
Why?
| Pneumonia, Viral | 1 | 2020 | 169 | 0.570 |
Why?
| Microtubules | 2 | 2016 | 36 | 0.570 |
Why?
| Transcription, Genetic | 5 | 2013 | 361 | 0.560 |
Why?
| Coronavirus Infections | 1 | 2020 | 178 | 0.560 |
Why?
| Cell Transformation, Neoplastic | 5 | 2017 | 181 | 0.550 |
Why?
| Research Design | 2 | 2019 | 353 | 0.550 |
Why?
| Rats, Inbred Strains | 6 | 2015 | 197 | 0.550 |
Why?
| Gene Expression Regulation | 7 | 2018 | 955 | 0.530 |
Why?
| Air Pollutants | 2 | 2017 | 64 | 0.520 |
Why?
| Epithelial Cells | 4 | 2015 | 207 | 0.520 |
Why?
| Environmental Health | 1 | 2016 | 9 | 0.520 |
Why?
| DNA | 3 | 2016 | 535 | 0.520 |
Why?
| Prostatic Hyperplasia | 3 | 2015 | 39 | 0.510 |
Why?
| Sexual Maturation | 1 | 2015 | 14 | 0.510 |
Why?
| Endoderm | 1 | 2015 | 2 | 0.510 |
Why?
| Diethylstilbestrol | 2 | 2008 | 12 | 0.510 |
Why?
| Embryo Implantation | 1 | 2015 | 7 | 0.510 |
Why?
| Diabetes, Gestational | 1 | 2016 | 52 | 0.510 |
Why?
| Transcriptional Activation | 3 | 2013 | 119 | 0.510 |
Why?
| Pandemics | 1 | 2020 | 562 | 0.500 |
Why?
| RNA, Untranslated | 1 | 2015 | 13 | 0.500 |
Why?
| Mesoderm | 1 | 2015 | 26 | 0.500 |
Why?
| Organoids | 1 | 2015 | 36 | 0.490 |
Why?
| Histone Code | 1 | 2015 | 30 | 0.490 |
Why?
| Dose-Response Relationship, Drug | 9 | 2020 | 1372 | 0.490 |
Why?
| Estrogen Receptor alpha | 6 | 2019 | 88 | 0.480 |
Why?
| Urinary Bladder Neck Obstruction | 1 | 2015 | 9 | 0.480 |
Why?
| Forkhead Transcription Factors | 2 | 2012 | 110 | 0.480 |
Why?
| SEER Program | 1 | 2015 | 94 | 0.470 |
Why?
| Cyclopentanes | 1 | 2014 | 10 | 0.470 |
Why?
| Quinolines | 1 | 2014 | 41 | 0.460 |
Why?
| Endocrinology | 1 | 2014 | 11 | 0.460 |
Why?
| Vehicle Emissions | 2 | 2017 | 9 | 0.450 |
Why?
| Cadmium | 2 | 2017 | 20 | 0.450 |
Why?
| Ovarian Neoplasms | 2 | 2010 | 450 | 0.450 |
Why?
| Fetal Blood | 3 | 2025 | 65 | 0.440 |
Why?
| Nerve Tissue Proteins | 2 | 2013 | 194 | 0.430 |
Why?
| Cell Differentiation | 2 | 2015 | 640 | 0.430 |
Why?
| Calcium-Binding Proteins | 2 | 2011 | 55 | 0.430 |
Why?
| Early Detection of Cancer | 1 | 2015 | 163 | 0.430 |
Why?
| Histone Acetyltransferases | 1 | 2013 | 21 | 0.430 |
Why?
| Toluene 2,4-Diisocyanate | 1 | 2013 | 1 | 0.430 |
Why?
| Diet | 2 | 2015 | 568 | 0.420 |
Why?
| Androgens | 4 | 2022 | 70 | 0.420 |
Why?
| Cell Division | 1 | 2014 | 291 | 0.420 |
Why?
| Transcriptome | 1 | 2015 | 314 | 0.420 |
Why?
| Integrin alpha6 | 1 | 2012 | 1 | 0.420 |
Why?
| Laminin | 1 | 2012 | 18 | 0.410 |
Why?
| RNA, Small Interfering | 6 | 2016 | 208 | 0.410 |
Why?
| Genetic Predisposition to Disease | 1 | 2015 | 510 | 0.410 |
Why?
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2012 | 1 | 0.410 |
Why?
| Dual-Specificity Phosphatases | 1 | 2012 | 2 | 0.400 |
Why?
| Oxidative Stress | 3 | 2007 | 772 | 0.400 |
Why?
| Firefighters | 1 | 2012 | 4 | 0.400 |
Why?
| Receptors, Androgen | 4 | 2022 | 45 | 0.400 |
Why?
| Interferon-gamma | 1 | 2013 | 177 | 0.400 |
Why?
| Gene-Environment Interaction | 1 | 2012 | 36 | 0.400 |
Why?
| Occupational Diseases | 1 | 2013 | 82 | 0.390 |
Why?
| Mass Screening | 1 | 2015 | 344 | 0.390 |
Why?
| HMGN Proteins | 1 | 2011 | 1 | 0.390 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 491 | 0.380 |
Why?
| Colorectal Neoplasms | 1 | 2015 | 260 | 0.380 |
Why?
| Endocrine Glands | 1 | 2011 | 5 | 0.370 |
Why?
| Endocrine System Diseases | 1 | 2011 | 9 | 0.370 |
Why?
| Risk | 4 | 2017 | 324 | 0.360 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 21 | 0.360 |
Why?
| RNA | 2 | 2012 | 163 | 0.360 |
Why?
| Gene Silencing | 2 | 2010 | 115 | 0.360 |
Why?
| Prolactin | 1 | 2010 | 44 | 0.350 |
Why?
| RNA, Messenger | 8 | 2022 | 1089 | 0.350 |
Why?
| Liver Neoplasms | 3 | 2024 | 327 | 0.350 |
Why?
| Membrane Proteins | 2 | 2010 | 332 | 0.350 |
Why?
| Introns | 1 | 2010 | 48 | 0.340 |
Why?
| Genetic Vectors | 1 | 2010 | 128 | 0.340 |
Why?
| Immunohistochemistry | 8 | 2016 | 957 | 0.340 |
Why?
| Placenta | 2 | 2025 | 134 | 0.340 |
Why?
| Sex Characteristics | 3 | 2018 | 198 | 0.340 |
Why?
| Proteins | 3 | 2008 | 339 | 0.330 |
Why?
| Anticarcinogenic Agents | 2 | 2006 | 32 | 0.320 |
Why?
| Disease Models, Animal | 7 | 2024 | 1436 | 0.320 |
Why?
| Histones | 5 | 2016 | 297 | 0.320 |
Why?
| Mice | 14 | 2024 | 5687 | 0.320 |
Why?
| Adult | 13 | 2025 | 13584 | 0.320 |
Why?
| Risk Factors | 5 | 2020 | 3723 | 0.310 |
Why?
| Orphan Nuclear Receptors | 2 | 2019 | 14 | 0.310 |
Why?
| Antigens, Neoplasm | 1 | 2009 | 148 | 0.300 |
Why?
| Polymerase Chain Reaction | 1 | 2009 | 449 | 0.290 |
Why?
| Deoxyguanosine | 2 | 2007 | 27 | 0.290 |
Why?
| Cells, Cultured | 7 | 2019 | 1571 | 0.290 |
Why?
| Organ Culture Techniques | 1 | 2007 | 47 | 0.290 |
Why?
| Ethinyl Estradiol | 2 | 2018 | 8 | 0.280 |
Why?
| Age Factors | 4 | 2015 | 1110 | 0.280 |
Why?
| Metabolome | 2 | 2025 | 94 | 0.280 |
Why?
| Apigenin | 1 | 2006 | 6 | 0.270 |
Why?
| Estrogen Receptor Modulators | 1 | 2006 | 5 | 0.270 |
Why?
| Cell Line | 4 | 2016 | 988 | 0.270 |
Why?
| Protein Isoforms | 4 | 2013 | 116 | 0.260 |
Why?
| Carcinoma, Hepatocellular | 2 | 2024 | 196 | 0.260 |
Why?
| Epithelium | 3 | 2014 | 66 | 0.260 |
Why?
| Antineoplastic Agents, Hormonal | 3 | 2014 | 49 | 0.260 |
Why?
| Proteomics | 1 | 2008 | 314 | 0.250 |
Why?
| Cytochrome P-450 CYP1A1 | 1 | 2005 | 26 | 0.240 |
Why?
| Middle Aged | 11 | 2020 | 12613 | 0.230 |
Why?
| NF-kappa B | 1 | 2006 | 315 | 0.230 |
Why?
| DNA-Binding Proteins | 3 | 2016 | 418 | 0.220 |
Why?
| Estrogen Antagonists | 2 | 2012 | 21 | 0.220 |
Why?
| Antioxidants | 1 | 2006 | 239 | 0.220 |
Why?
| Mice, Knockout | 2 | 2024 | 844 | 0.220 |
Why?
| Base Sequence | 4 | 2012 | 639 | 0.220 |
Why?
| Wnt Signaling Pathway | 1 | 2024 | 86 | 0.220 |
Why?
| beta Catenin | 1 | 2024 | 97 | 0.220 |
Why?
| Stem Cells | 2 | 2015 | 166 | 0.210 |
Why?
| Interferons | 2 | 2015 | 38 | 0.210 |
Why?
| Kidney | 1 | 2007 | 696 | 0.210 |
Why?
| Tumor Suppressor Proteins | 2 | 2020 | 128 | 0.200 |
Why?
| Immediate-Early Proteins | 1 | 2002 | 19 | 0.200 |
Why?
| Pregnancy Outcome | 2 | 2017 | 207 | 0.200 |
Why?
| Reproducibility of Results | 5 | 2020 | 1199 | 0.200 |
Why?
| Arabidopsis Proteins | 1 | 2002 | 24 | 0.190 |
Why?
| Inheritance Patterns | 1 | 2021 | 22 | 0.190 |
Why?
| Molecular Sequence Data | 4 | 2012 | 778 | 0.190 |
Why?
| Incineration | 1 | 2021 | 5 | 0.190 |
Why?
| Testis | 1 | 2021 | 66 | 0.190 |
Why?
| HEK293 Cells | 4 | 2016 | 213 | 0.180 |
Why?
| Maternal Nutritional Physiological Phenomena | 1 | 2021 | 55 | 0.180 |
Why?
| Loneliness | 1 | 2020 | 12 | 0.180 |
Why?
| Hypesthesia | 1 | 2020 | 17 | 0.180 |
Why?
| Infant, Newborn | 4 | 2025 | 2749 | 0.180 |
Why?
| Mammary Glands, Animal | 2 | 2020 | 69 | 0.180 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2008 | 405 | 0.180 |
Why?
| Chromatin Immunoprecipitation | 3 | 2016 | 48 | 0.180 |
Why?
| Memory Disorders | 1 | 2020 | 53 | 0.170 |
Why?
| Tissue Array Analysis | 4 | 2016 | 45 | 0.170 |
Why?
| DNA Modification Methylases | 1 | 2020 | 28 | 0.170 |
Why?
| Isocitrate Dehydrogenase | 1 | 2020 | 18 | 0.170 |
Why?
| Maternal-Fetal Exchange | 1 | 2020 | 42 | 0.170 |
Why?
| DNA Repair Enzymes | 1 | 2020 | 43 | 0.170 |
Why?
| Pyruvate Kinase | 1 | 2020 | 7 | 0.170 |
Why?
| Carcinogens | 2 | 2015 | 196 | 0.170 |
Why?
| Animals, Newborn | 4 | 2018 | 363 | 0.170 |
Why?
| Phenotype | 2 | 2015 | 739 | 0.170 |
Why?
| Fear | 1 | 2020 | 84 | 0.170 |
Why?
| Sequence Analysis, RNA | 1 | 2020 | 89 | 0.170 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 181 | 0.170 |
Why?
| Random Allocation | 2 | 2017 | 289 | 0.170 |
Why?
| Methylation | 2 | 2020 | 118 | 0.160 |
Why?
| Mice, Transgenic | 2 | 2015 | 540 | 0.160 |
Why?
| Neoplasm Metastasis | 2 | 2014 | 232 | 0.160 |
Why?
| Glioma | 1 | 2020 | 77 | 0.160 |
Why?
| Endometrial Neoplasms | 1 | 2020 | 137 | 0.160 |
Why?
| Blotting, Western | 3 | 2016 | 578 | 0.160 |
Why?
| Image Processing, Computer-Assisted | 2 | 2016 | 246 | 0.160 |
Why?
| Collagen Type III | 1 | 2019 | 6 | 0.160 |
Why?
| Subcellular Fractions | 2 | 2012 | 33 | 0.160 |
Why?
| Gonadal Steroid Hormones | 2 | 2011 | 41 | 0.160 |
Why?
| Adaptation, Psychological | 1 | 2020 | 227 | 0.160 |
Why?
| Urethra | 2 | 2020 | 91 | 0.160 |
Why?
| Protein Binding | 3 | 2011 | 654 | 0.160 |
Why?
| Liver Failure, Acute | 1 | 2019 | 56 | 0.150 |
Why?
| Methylmercury Compounds | 1 | 2018 | 5 | 0.150 |
Why?
| Collagen Type I | 1 | 2019 | 81 | 0.150 |
Why?
| Cohort Studies | 2 | 2014 | 1452 | 0.150 |
Why?
| Linear Models | 1 | 2019 | 279 | 0.150 |
Why?
| DNA Primers | 2 | 2011 | 206 | 0.150 |
Why?
| Hair | 1 | 2018 | 25 | 0.150 |
Why?
| Denmark | 1 | 2018 | 55 | 0.150 |
Why?
| Polychlorinated Biphenyls | 1 | 2018 | 28 | 0.150 |
Why?
| Computational Biology | 2 | 2017 | 215 | 0.150 |
Why?
| Electronic Waste | 1 | 2017 | 1 | 0.150 |
Why?
| Lysine | 2 | 2015 | 84 | 0.150 |
Why?
| T-Lymphocytes | 2 | 2017 | 325 | 0.150 |
Why?
| Water Pollutants, Chemical | 1 | 2018 | 43 | 0.150 |
Why?
| Survival Analysis | 2 | 2016 | 661 | 0.140 |
Why?
| Histone Demethylases | 1 | 2017 | 17 | 0.140 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2017 | 26 | 0.140 |
Why?
| Urethane | 1 | 2017 | 5 | 0.140 |
Why?
| Neoplasm Staging | 2 | 2014 | 746 | 0.140 |
Why?
| Antigens, CD1 | 1 | 2017 | 8 | 0.140 |
Why?
| Antigen Presentation | 1 | 2017 | 25 | 0.140 |
Why?
| Models, Biological | 4 | 2017 | 716 | 0.140 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2019 | 213 | 0.140 |
Why?
| Tumor Cells, Cultured | 2 | 2014 | 457 | 0.140 |
Why?
| Aged | 8 | 2020 | 9743 | 0.140 |
Why?
| Fibroblasts | 1 | 2019 | 336 | 0.140 |
Why?
| Acetylation | 2 | 2015 | 94 | 0.140 |
Why?
| Cholesterol | 1 | 2017 | 150 | 0.130 |
Why?
| Brain Neoplasms | 1 | 2020 | 291 | 0.130 |
Why?
| 5-Methylcytosine | 1 | 2016 | 16 | 0.130 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2014 | 212 | 0.130 |
Why?
| Hippocampus | 1 | 2018 | 222 | 0.130 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 14 | 0.130 |
Why?
| Genetic Loci | 1 | 2016 | 45 | 0.130 |
Why?
| Methyltransferases | 1 | 2016 | 30 | 0.130 |
Why?
| Exercise | 1 | 2020 | 516 | 0.130 |
Why?
| Young Adult | 5 | 2025 | 4107 | 0.130 |
Why?
| Heart Diseases | 1 | 2019 | 213 | 0.130 |
Why?
| Myocardium | 1 | 2019 | 445 | 0.130 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 54 | 0.130 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2015 | 3 | 0.130 |
Why?
| Genital Neoplasms, Male | 1 | 2015 | 2 | 0.130 |
Why?
| Prognosis | 3 | 2017 | 1977 | 0.130 |
Why?
| Exosomes | 1 | 2016 | 48 | 0.130 |
Why?
| Gene Expression | 2 | 2011 | 610 | 0.130 |
Why?
| Immunologic Surveillance | 1 | 2015 | 11 | 0.130 |
Why?
| Environment | 1 | 2016 | 81 | 0.120 |
Why?
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2015 | 50 | 0.120 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 106 | 0.120 |
Why?
| Cell Survival | 2 | 2008 | 589 | 0.120 |
Why?
| Myeloid Cells | 1 | 2015 | 37 | 0.120 |
Why?
| Incidence | 2 | 2017 | 1032 | 0.120 |
Why?
| Prostatectomy | 1 | 2016 | 82 | 0.120 |
Why?
| Mammaglobin B | 1 | 2015 | 1 | 0.120 |
Why?
| Genital Neoplasms, Female | 1 | 2015 | 41 | 0.120 |
Why?
| Lung Neoplasms | 2 | 2020 | 600 | 0.120 |
Why?
| Cluster Analysis | 1 | 2015 | 219 | 0.120 |
Why?
| Age Distribution | 1 | 2015 | 170 | 0.120 |
Why?
| Urinary Bladder | 1 | 2015 | 93 | 0.120 |
Why?
| Hyperplasia | 1 | 2015 | 96 | 0.120 |
Why?
| Schools | 1 | 2016 | 164 | 0.120 |
Why?
| Up-Regulation | 4 | 2019 | 446 | 0.120 |
Why?
| Inflammasomes | 1 | 2015 | 62 | 0.120 |
Why?
| Gestational Age | 1 | 2016 | 373 | 0.120 |
Why?
| Polycomb Repressive Complex 2 | 1 | 2014 | 46 | 0.120 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 137 | 0.120 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2014 | 20 | 0.110 |
Why?
| History, 21st Century | 1 | 2014 | 56 | 0.110 |
Why?
| Protein Processing, Post-Translational | 2 | 2012 | 156 | 0.110 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 127 | 0.110 |
Why?
| History, 20th Century | 1 | 2014 | 100 | 0.110 |
Why?
| Kaplan-Meier Estimate | 2 | 2017 | 464 | 0.110 |
Why?
| Gene Deletion | 1 | 2015 | 261 | 0.110 |
Why?
| Neoplasm Proteins | 1 | 2016 | 320 | 0.110 |
Why?
| Age of Onset | 1 | 2014 | 108 | 0.110 |
Why?
| Repressor Proteins | 1 | 2014 | 148 | 0.110 |
Why?
| Tamoxifen | 2 | 2012 | 60 | 0.110 |
Why?
| Methacholine Chloride | 1 | 2013 | 3 | 0.110 |
Why?
| Sp1 Transcription Factor | 2 | 2024 | 22 | 0.110 |
Why?
| Metabolomics | 2 | 2025 | 135 | 0.100 |
Why?
| Exons | 1 | 2013 | 93 | 0.100 |
Why?
| MAP Kinase Kinase Kinase 1 | 1 | 2012 | 4 | 0.100 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 128 | 0.100 |
Why?
| Oncogene Proteins | 1 | 2012 | 16 | 0.100 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2012 | 65 | 0.100 |
Why?
| Saliva | 1 | 2012 | 55 | 0.100 |
Why?
| Ovary | 2 | 2020 | 103 | 0.100 |
Why?
| Eyelids | 1 | 2012 | 29 | 0.100 |
Why?
| Smoke | 1 | 2012 | 18 | 0.100 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2012 | 36 | 0.100 |
Why?
| In Situ Hybridization | 2 | 2010 | 66 | 0.100 |
Why?
| Cell Adhesion | 1 | 2012 | 157 | 0.100 |
Why?
| Mice, Nude | 4 | 2014 | 248 | 0.100 |
Why?
| RNA Splicing | 1 | 2012 | 38 | 0.100 |
Why?
| Flow Cytometry | 2 | 2014 | 474 | 0.100 |
Why?
| Antibodies | 2 | 2012 | 153 | 0.100 |
Why?
| Azacitidine | 1 | 2011 | 34 | 0.100 |
Why?
| Phytoestrogens | 2 | 2014 | 22 | 0.100 |
Why?
| Phosphorylation | 3 | 2020 | 525 | 0.100 |
Why?
| Carrier Proteins | 1 | 2013 | 298 | 0.090 |
Why?
| Adult Stem Cells | 1 | 2011 | 10 | 0.090 |
Why?
| Peptide Hormones | 1 | 2011 | 4 | 0.090 |
Why?
| Cell Cycle | 2 | 2012 | 226 | 0.090 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2011 | 34 | 0.090 |
Why?
| Thyroid Hormones | 1 | 2011 | 20 | 0.090 |
Why?
| Biomedical Research | 1 | 2014 | 244 | 0.090 |
Why?
| Calcitriol | 1 | 2011 | 39 | 0.090 |
Why?
| Tubulin Modulators | 1 | 2011 | 27 | 0.090 |
Why?
| Calgranulin B | 1 | 2010 | 4 | 0.090 |
Why?
| Bromocriptine | 1 | 2010 | 4 | 0.090 |
Why?
| Chemokine CXCL13 | 1 | 2010 | 5 | 0.090 |
Why?
| Muscle Proteins | 1 | 2013 | 320 | 0.090 |
Why?
| Tretinoin | 1 | 2011 | 50 | 0.090 |
Why?
| Nitric Oxide | 1 | 2012 | 259 | 0.090 |
Why?
| Models, Genetic | 1 | 2011 | 172 | 0.090 |
Why?
| Cell Nucleus | 2 | 2016 | 182 | 0.090 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 861 | 0.090 |
Why?
| Paclitaxel | 1 | 2011 | 84 | 0.090 |
Why?
| Microscopy, Confocal | 1 | 2010 | 83 | 0.090 |
Why?
| Feedback, Physiological | 1 | 2010 | 12 | 0.090 |
Why?
| Genes, abl | 1 | 2010 | 2 | 0.090 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 72 | 0.090 |
Why?
| Autoimmunity | 1 | 2010 | 34 | 0.090 |
Why?
| Staining and Labeling | 2 | 2016 | 96 | 0.090 |
Why?
| Interleukin-1beta | 1 | 2010 | 72 | 0.080 |
Why?
| Microscopy, Fluorescence | 1 | 2010 | 158 | 0.080 |
Why?
| Molecular Targeted Therapy | 1 | 2011 | 123 | 0.080 |
Why?
| Mice, Inbred C57BL | 4 | 2019 | 1808 | 0.080 |
Why?
| Binding Sites | 2 | 2022 | 362 | 0.080 |
Why?
| Disease-Free Survival | 1 | 2010 | 444 | 0.080 |
Why?
| Follow-Up Studies | 1 | 2014 | 2242 | 0.080 |
Why?
| Proportional Hazards Models | 1 | 2010 | 415 | 0.080 |
Why?
| Ecotoxicology | 1 | 2008 | 4 | 0.080 |
Why?
| Administration, Oral | 2 | 2010 | 434 | 0.080 |
Why?
| Genital Diseases, Female | 1 | 2008 | 17 | 0.080 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 28 | 0.080 |
Why?
| Public Health Practice | 1 | 2008 | 40 | 0.080 |
Why?
| Behavior, Animal | 2 | 2020 | 178 | 0.070 |
Why?
| Apoptosis | 1 | 2013 | 1097 | 0.070 |
Why?
| Drug Resistance, Neoplasm | 1 | 2010 | 316 | 0.070 |
Why?
| NADH, NADPH Oxidoreductases | 1 | 2007 | 13 | 0.070 |
Why?
| Microdissection | 1 | 2007 | 18 | 0.070 |
Why?
| Cyclooxygenase 2 | 1 | 2007 | 43 | 0.070 |
Why?
| Nitric Oxide Synthase | 1 | 2007 | 74 | 0.070 |
Why?
| Lasers | 1 | 2007 | 106 | 0.070 |
Why?
| Presenilin-2 | 1 | 2006 | 3 | 0.070 |
Why?
| Yeasts | 1 | 2006 | 10 | 0.070 |
Why?
| Sequence Analysis, Protein | 1 | 2006 | 19 | 0.070 |
Why?
| Dimerization | 1 | 2006 | 51 | 0.070 |
Why?
| Caspase 3 | 1 | 2006 | 93 | 0.070 |
Why?
| Proteome | 1 | 2008 | 169 | 0.070 |
Why?
| Protein Biosynthesis | 2 | 2013 | 232 | 0.070 |
Why?
| Retrospective Studies | 2 | 2016 | 6264 | 0.070 |
Why?
| Consensus | 1 | 2007 | 160 | 0.070 |
Why?
| Growth Differentiation Factor 1 | 1 | 2006 | 2 | 0.070 |
Why?
| United States | 2 | 2015 | 4955 | 0.070 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2008 | 393 | 0.070 |
Why?
| Oxidation-Reduction | 1 | 2007 | 316 | 0.070 |
Why?
| Enzyme Activation | 1 | 2006 | 268 | 0.060 |
Why?
| Spinacia oleracea | 1 | 2006 | 7 | 0.060 |
Why?
| Interleukin-12 | 1 | 2006 | 29 | 0.060 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 46 | 0.060 |
Why?
| Interleukin-8 | 1 | 2006 | 85 | 0.060 |
Why?
| Phytotherapy | 1 | 2006 | 45 | 0.060 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 102 | 0.060 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1172 | 0.060 |
Why?
| Models, Molecular | 1 | 2006 | 334 | 0.060 |
Why?
| Amino Acid Sequence | 1 | 2006 | 574 | 0.060 |
Why?
| Phthalic Acids | 1 | 2025 | 4 | 0.060 |
Why?
| MCF-7 Cells | 2 | 2016 | 62 | 0.060 |
Why?
| Alternative Splicing | 1 | 2005 | 53 | 0.060 |
Why?
| Oxygen Consumption | 1 | 2006 | 191 | 0.060 |
Why?
| Leukocytes, Mononuclear | 1 | 2025 | 118 | 0.060 |
Why?
| Isoenzymes | 1 | 2005 | 168 | 0.060 |
Why?
| TATA Box | 1 | 2004 | 9 | 0.060 |
Why?
| Dinucleoside Phosphates | 1 | 2004 | 6 | 0.060 |
Why?
| Adolescent | 1 | 2016 | 6446 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2017 | 326 | 0.060 |
Why?
| Transfection | 1 | 2005 | 356 | 0.060 |
Why?
| Infant | 1 | 2012 | 3629 | 0.060 |
Why?
| Tandem Mass Spectrometry | 2 | 2017 | 238 | 0.060 |
Why?
| Child, Preschool | 1 | 2012 | 3943 | 0.060 |
Why?
| Orchiectomy | 1 | 2003 | 38 | 0.060 |
Why?
| Oxidoreductases | 1 | 2003 | 59 | 0.050 |
Why?
| Precancerous Conditions | 1 | 2004 | 82 | 0.050 |
Why?
| Androgen-Binding Protein | 1 | 2003 | 1 | 0.050 |
Why?
| Prostatic Secretory Proteins | 1 | 2003 | 1 | 0.050 |
Why?
| Seminal Vesicle Secretory Proteins | 1 | 2003 | 1 | 0.050 |
Why?
| Plant Extracts | 1 | 2006 | 174 | 0.050 |
Why?
| Regeneration | 1 | 2003 | 58 | 0.050 |
Why?
| Peptide Elongation Factor 1 | 1 | 2003 | 2 | 0.050 |
Why?
| Aldehydes | 1 | 2003 | 82 | 0.050 |
Why?
| Clusterin | 1 | 2003 | 6 | 0.050 |
Why?
| Glucosephosphate Dehydrogenase | 1 | 2003 | 6 | 0.050 |
Why?
| Amino Acyl-tRNA Synthetases | 1 | 2003 | 6 | 0.050 |
Why?
| Glutathione Reductase | 1 | 2003 | 14 | 0.050 |
Why?
| Glutathione Peroxidase | 1 | 2003 | 23 | 0.050 |
Why?
| Postoperative Period | 1 | 2003 | 171 | 0.050 |
Why?
| Cytoskeleton | 1 | 2003 | 39 | 0.050 |
Why?
| Malondialdehyde | 1 | 2003 | 51 | 0.050 |
Why?
| Catalase | 1 | 2003 | 67 | 0.050 |
Why?
| Lipid Peroxidation | 1 | 2003 | 96 | 0.050 |
Why?
| Molecular Chaperones | 1 | 2003 | 61 | 0.050 |
Why?
| Alkaline Phosphatase | 1 | 2003 | 93 | 0.050 |
Why?
| Superoxide Dismutase | 1 | 2003 | 116 | 0.050 |
Why?
| Glycoproteins | 1 | 2003 | 116 | 0.050 |
Why?
| Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2002 | 1 | 0.050 |
Why?
| Receptors, Vasoactive Intestinal Peptide | 1 | 2002 | 3 | 0.050 |
Why?
| Radioimmunoassay | 1 | 2002 | 43 | 0.050 |
Why?
| Peer Review | 1 | 2002 | 9 | 0.050 |
Why?
| Risk Assessment | 3 | 2015 | 1269 | 0.050 |
Why?
| Endocrine System | 1 | 2002 | 16 | 0.050 |
Why?
| Early Growth Response Protein 1 | 1 | 2002 | 34 | 0.050 |
Why?
| Neoplasm Invasiveness | 2 | 2014 | 269 | 0.050 |
Why?
| Sp3 Transcription Factor | 1 | 2022 | 5 | 0.050 |
Why?
| STAT3 Transcription Factor | 1 | 2002 | 77 | 0.050 |
Why?
| RNA Polymerase II | 1 | 2022 | 12 | 0.050 |
Why?
| Adenosine Triphosphatases | 1 | 2002 | 87 | 0.050 |
Why?
| Plant Proteins | 1 | 2002 | 68 | 0.050 |
Why?
| Mutation | 1 | 2007 | 1281 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 245 | 0.050 |
Why?
| Mitochondria | 1 | 2005 | 399 | 0.050 |
Why?
| Amino Acids | 1 | 2023 | 373 | 0.050 |
Why?
| Trans-Activators | 1 | 2002 | 134 | 0.050 |
Why?
| Reactive Oxygen Species | 1 | 2003 | 409 | 0.050 |
Why?
| Alcohol Oxidoreductases | 1 | 2020 | 13 | 0.040 |
Why?
| Child | 1 | 2012 | 6910 | 0.040 |
Why?
| Lymphangioleiomyomatosis | 1 | 2020 | 4 | 0.040 |
Why?
| Thyroid Gland | 1 | 2020 | 75 | 0.040 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2020 | 134 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2019 | 36 | 0.040 |
Why?
| Acetylcysteine | 1 | 2019 | 101 | 0.040 |
Why?
| Transcription Factors | 1 | 2002 | 565 | 0.040 |
Why?
| Rats, Wistar | 1 | 2019 | 224 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2023 | 1608 | 0.040 |
Why?
| Fibrosis | 1 | 2019 | 181 | 0.040 |
Why?
| Biopsy | 1 | 2020 | 588 | 0.040 |
Why?
| Apgar Score | 1 | 2017 | 26 | 0.040 |
Why?
| Pilot Projects | 1 | 2020 | 699 | 0.040 |
Why?
| Heart | 1 | 2020 | 339 | 0.040 |
Why?
| Diet, Atherogenic | 1 | 2017 | 8 | 0.040 |
Why?
| China | 1 | 2017 | 90 | 0.040 |
Why?
| Gasoline | 1 | 2017 | 2 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 39 | 0.040 |
Why?
| Injections, Intraperitoneal | 1 | 2017 | 59 | 0.040 |
Why?
| Birth Weight | 1 | 2017 | 106 | 0.030 |
Why?
| Endosomes | 1 | 2017 | 32 | 0.030 |
Why?
| Endocytosis | 1 | 2017 | 55 | 0.030 |
Why?
| Time Factors | 2 | 2014 | 2935 | 0.030 |
Why?
| Sex Factors | 1 | 2019 | 711 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 170 | 0.030 |
Why?
| Acetaminophen | 1 | 2019 | 276 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2017 | 175 | 0.030 |
Why?
| Lung | 1 | 2020 | 504 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 226 | 0.030 |
Why?
| Hormone Replacement Therapy | 1 | 2015 | 33 | 0.030 |
Why?
| Drug Implants | 1 | 2015 | 35 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 140 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2015 | 122 | 0.030 |
Why?
| Models, Theoretical | 1 | 2016 | 170 | 0.030 |
Why?
| Organ Size | 1 | 2015 | 225 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2015 | 164 | 0.030 |
Why?
| Sp Transcription Factors | 1 | 2014 | 7 | 0.030 |
Why?
| Pentacyclic Triterpenes | 1 | 2014 | 8 | 0.030 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2015 | 69 | 0.030 |
Why?
| Triterpenes | 1 | 2014 | 11 | 0.030 |
Why?
| Neoplasm Transplantation | 1 | 2014 | 86 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2014 | 75 | 0.030 |
Why?
| HMGA Proteins | 1 | 2014 | 2 | 0.030 |
Why?
| Immunity, Innate | 1 | 2015 | 105 | 0.030 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 66 | 0.030 |
Why?
| Caspase 7 | 1 | 2013 | 6 | 0.030 |
Why?
| Genome | 1 | 2014 | 64 | 0.030 |
Why?
| 5' Untranslated Regions | 1 | 2013 | 25 | 0.030 |
Why?
| Open Reading Frames | 1 | 2013 | 47 | 0.030 |
Why?
| Life Style | 1 | 2014 | 144 | 0.030 |
Why?
| Transcription Factor AP-2 | 1 | 2012 | 3 | 0.030 |
Why?
| Laser Capture Microdissection | 1 | 2012 | 6 | 0.030 |
Why?
| Receptors, Steroid | 1 | 2012 | 19 | 0.030 |
Why?
| Progesterone | 1 | 2012 | 57 | 0.030 |
Why?
| DNA, Complementary | 1 | 2012 | 133 | 0.030 |
Why?
| Tissue Distribution | 1 | 2012 | 166 | 0.030 |
Why?
| Serum Response Factor | 1 | 2012 | 40 | 0.030 |
Why?
| Cell Death | 1 | 2012 | 175 | 0.020 |
Why?
| Doxorubicin | 1 | 2013 | 236 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 80 | 0.020 |
Why?
| Cisplatin | 1 | 2013 | 286 | 0.020 |
Why?
| Neoplasm Recurrence, Local | 1 | 2016 | 629 | 0.020 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 93 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2012 | 117 | 0.020 |
Why?
| Genotype | 1 | 2012 | 532 | 0.020 |
Why?
| Albumins | 1 | 2011 | 31 | 0.020 |
Why?
| Inhibitory Concentration 50 | 1 | 2011 | 69 | 0.020 |
Why?
| Microarray Analysis | 1 | 2011 | 70 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 2010 | 52 | 0.020 |
Why?
| STAT1 Transcription Factor | 1 | 2010 | 26 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2011 | 296 | 0.020 |
Why?
| Carcinoma, Lobular | 1 | 2010 | 33 | 0.020 |
Why?
| Receptors, Progesterone | 1 | 2010 | 64 | 0.020 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 45 | 0.020 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2010 | 91 | 0.020 |
Why?
| Nanoparticles | 1 | 2011 | 152 | 0.020 |
Why?
| Drug Delivery Systems | 1 | 2011 | 143 | 0.020 |
Why?
| Dihydrotestosterone | 1 | 2007 | 12 | 0.020 |
Why?
| United States Environmental Protection Agency | 1 | 2007 | 7 | 0.020 |
Why?
| Animals, Wild | 1 | 2007 | 9 | 0.020 |
Why?
| North Carolina | 1 | 2007 | 52 | 0.020 |
Why?
| National Institutes of Health (U.S.) | 1 | 2007 | 44 | 0.020 |
Why?
| Models, Animal | 1 | 2007 | 227 | 0.020 |
Why?
| Down-Regulation | 1 | 2007 | 340 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2010 | 3227 | 0.010 |
Why?
| Public Health | 1 | 2002 | 199 | 0.010 |
Why?
|
|
Ho's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|